Levofloxacin Hydrochloride Capsules

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-fluoro-7H pyridinebenzene Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-fluoro-7H pyridinebenzene Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-fluoro-7H pyridinebenzene

This product is a capsule, and the contents are off-white or light yellow powder.

This product is suitable for the following mild and severe infections caused by sensitive bacteria: 1. Respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis complicated with infection, pneumonia, tonsillitis (peritonsillar abscess); 2. Urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; 3. Reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); 4. Skin Skin and soft tissue infections: infectious impetigo, cellulitis, lymphangitis (adenitis), subcutaneous abscess, perianal abscess, etc.; 5. Intestinal infections: bacterial dysentery, infectious enteritis, Salmonella enteritis, typhoid and paratyphoid; 6. Various infections in patients with sepsis, neutropenia and immunodeficiency; 7. Other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (use metronidazole in combination when necessary), cholecystitis, cholangitis, bone and joint infections, and ENT infections, etc.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms, as well as rash, itching and other symptoms may occur. Transient liver function abnormalities may also occur, such as increased serum transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the treatment.

1. Those who are allergic to quinolones; 2. Pregnant and lactating women; 3. Patients under 18 years old are prohibited from using this product.

Precautions for children: Patients under 18 years old are prohibited to use. Precautions for pregnancy and lactation: Pregnant and lactating women. Precautions for the elderly: Elderly patients should use with caution. Generally, 100 mg (1 tablet) is used once, twice a day, and the interval between medications should be noted.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2b), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. This product has little effect on the metabolism of theophylline, but the blood concentration of theophylline should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2b), and may cause central nervous system toxicity. 7. Acid-reducing drugs and iron preparations containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8. When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions may occasionally occur, so it is not suitable for use with fenbufen.

Keep away from light and store in sealed container.

0.1 g according to C18H20FN304

24 months.

Yangtze River Pharmaceutical (Group) Co., Ltd.

• Founded in:

  2001-03-27

• Address:

  No. 1, South Yangtze River Road, Taizhou

• Tax NO.:

  913212007286987632

• Registered Funds:

  133 million yuan

• Website:

  Log in to view

• Email:

  Log in to view